Vimpat
Active Ingredient(s): LacosamideFDA Approved: * October 28, 2008
Pharm Company: * SCHWARZ BIOSCIENCES
Category: Anticonvulsant
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.[1] It is used by mouth or intravenously.[1] It is available as a generic medication.[2] Contents 1 Medical uses 1.1 Off-label use 2 Contraindications 3 Side effects 3.1 Gastrointestinal 3.2 Central nervous system 3.3 Psychiatric 3.4 Cardiovascular 3.5 Allergies 3.6 Warnin... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.37 Discussions
Dosage List
Related Brands
Drugs with the same active ingredientsPopular Topics
i'm female and 59. had epilepsy since birth. it disappeared when periods came but returned when 2nd baby was born. h...
18 REPLIESDoes anyone else take Vimpat along with Lamictal? I started having a severe side effect when I added Vimpat to help cont...
10 REPLIESI am taking Vimpat 800 mg, and I would like to know more about this medication. ## Be careful with whatever medicine(s) ...
5 REPLIESmy son just switched from levetraceta/Kepra to Vimpat. he uses 7.5 ml 2x daily once in the morning and one dose early ev...
4 REPLIESThis is to William who I can't click on to reply. He hasn't taken Vimpat yet and wants to know more about it. Ho...
3 REPLIESI was taking Vimpat in 2012 and 2013. I was recently diagnosed with Leukemia (CML). Has anyone been diagnosed with Leuke...
2 REPLIESMy boyfriend is on depakota ER, and Vimpat. Previously he was on gabapentin, which stopped working. So Vimpat replaced t...
1 REPLYHello, I have been on vimpat for a little over a year. No complaints. I take 200 mg twice a day. I am wondering how long...
1 REPLYhi I've been on vimpat for 6 month no seizers since my problem is the stomach and heart burn that came along with it...
1 REPLYSince being on Vimpat, I have gotten shortness of breath (SoB), when ever I do any exercise, walking 3 blocks required a...
1 REPLY